NAV
$64.98
AUM
$161.8M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.99
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +26.71% | +28.46% | +21.17% | +114.50% | +28.93% | +6.29% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | ALKS | Alkermes PLC | 4.48% |
| 2 | KYMR | Kymera Therapeutics Inc Ordinary Shares | 4.23% |
| 3 | CELC | Celcuity Inc | 3.92% |
| 4 | MIRM | Mirum Pharmaceuticals Inc | 3.90% |
| 5 | SYRE | Spyre Therapeutics Inc | 3.68% |
| 6 | CGON | CG Oncology Inc | 3.35% |
| 7 | APGE | Apogee Therapeutics Inc | 2.93% |
| 8 | XENE | Xenon Pharmaceuticals Inc | 2.90% |
| 9 | TVTX | Travere Therapeutics Inc Ordinary Shares | 2.77% |
| 10 | DNTH | Dianthus Therapeutics Inc | 2.64% |
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Inception Date: 2014-12-30